Neuroleptic malignant syndrome and atypical antipsychotics: A brief review;Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature

Encephale

Volumn 34, Issue 6, 2008, Pages 618-624

  Khaldi, S ^a   Kornreich, C ^b   Choubani, Z ^c   Gourevitch, R ^d,e  

^a centre hospitalo universitaire Brugmann ^*  (Tunisia)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c RAZI HOSPITAL   (Tunisia)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

^e INSERM   (France)

Author keywords

Amisulpride; Atypical antipsychotics; Clozapine; Neuroleptic malignant syndrome; Olanzapine; Quetiapine; Risperidone; Side effects; Ziprasidone

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; LITHIUM; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; MENTAL DEFICIENCY; NEUROLEPTIC MALIGNANT SYNDROME; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX RATIO; SHORT SURVEY;

EID: 57249088709     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2007.11.007     Document Type: Short Survey

References (56)

1. Aboraya A., Schumacher J., Abdalla E., et al. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. W V Med J 98 (2002) 63-65
2. Abu-Kishk I., Tolendo M., Reis A., et al. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J Toxicol Clin Toxicol 42 (2004) 921-925
3. Addonizio G., Susman V.L., and Roth S.D. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22 (1987) 1004-1020
4. Ananth J., Parameswaran S., Gunatilake S., et al. Neuroleptic malignant syndrome and atypical antipsychotics drugs. J Clin Psychiatry 65 (2004) 464-470
5. Apple J.E., and van Hauer G. Neuroleptic malignant syndrome associated with olanzapine therapy. Psychosomatics 40 (1999) 267-268
6. Arnaout M.S., Antun F.P., and Ashkar K. Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Hum Psychopharmacol 16 (2001) 279-281
7. Beauchemin M.A., Millaut F., and Khoa N. A case of neuroleptic malignant syndrom with clozapine and risperidone. Can J Psychiatry 47 (2002) 886
8. Berry N., Pradhan S., Sagar R., et al. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 23 (2003) 255-259
9. Buckley P.F., and Meltzer H.Y. Treatment of schizophrenia. Textbook of psychopharmacology (1995), American Psychiatric Press, Washington, DC 615-639
10. Chatterton R., Cardy S., and Schramm T.M. Neuroleptic malignant syndrome and clozapine monotherapy. Aust N Z J Psychiatry 30 (1996) 692-693
11. DasGupta K., and Young A. Clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52 (1991) 105-107
12. Dave M., Singer S., Richards C., et al. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 152 (1995) 1233-1234
13. Delay J., Pichot P., Lemperière T., et al. Un neuroleptique majeur non phénothiazine et non réserpine, l'halopéridol dans le traitement des psychoses. Ann Med Psychol 118 (1960) 145-152
14. Diagnostic and stastical manuel of mental disorders. 4th ed. American psychiatric association. (Washington DC, 1994). Traduction française par J-D Guelfi, et al. Paris: Masson; 1996.
15. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskr Laeg 161 (1999) 1424-1425 [abstract]
16. Filice G.A., McDougall B.C., Ercan-Fang N., et al. Neuroleptic maligant syndrome associated with olanzapine. Ann Pharmacother 32 (1998) 1158-1159
17. Ganelin L., Lichtenberg P.S., Marcus E.L., et al. Suspected neuroleptic malignant syndrome in a patient receiving clozapine. Ann Pharmacother 30 (1996) 248-250
18. Garcia Lopez M.M., Cipres L., De Centra, et al. Neuroleptic malignant syndrome associated with olanzapine. Med Clin 113 (1999) 239
19. Gheorghiu S., Knobler H.Y., and Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine. Am J Psychiatry 156 (1999) 1836
20. Hassan S., and Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 155 (1998) 1113-1116
21. Hall K.L., Taylor W.H., and Ware M.R. Neuroleptic malignant syndrome due to olanzapine. Psychopharmacol Bull 35 (2001) 49-54
22. Hanft A., Eggleston C.F., and Bourgeois J.A. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine. J Child Adolesc Psychopharmacol 14 (2004) 481-487
23. Hester S., Bronson B., and Martin R. Neuroleptic malignant syndrome and low-dose onalzapine. Am J Psychiatry 160 (2003) 4
24. Huang T.L. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. Chang Gung Med J 24 (2001) 522-525
25. Johnson V., and Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry 32 (1998) 884-886
26. Khaldi S., Gourevitch R., Matmar M., et al. Necrotizing enterocolitis after antipsychotic treatment involving clozapine and review of severe digestive complications. A case report. Pharmacopsychiatry 38 (2005) 220-221
27. Kopf A., Koster J., Schulz A., et al. Life threatening neuroleptic malignant syndrome due to olanzapine. Psychiatr Prax 30 (2003) 279-282
28. Kontaxakis V.P., Havaki-Kontaxaki B.J., Stamouli S.S., et al. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 407-409
29. Lazarus A., Mann S.C., and Caroff S.N. The neuroleptic malignant syndrom and related conditions (1989), Am Psychiatric Press, Washington DC
30. Lee H., Ryan J., Mullett G., and Lawlor B.A. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol 9 (1994) 303-305
31. Leibold J., Patel V., and Hasan R.A. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 26 (2004) 1105-1108
32. Levenson J.L. Neuroleptic malignant syndrome after the initiation of olanzapine. J Clin Psychopharmacol 19 (1999) 477-478
33. Levin G.M., Lazowick A.L., and Powell H.S. Neuroleptic malignant syndrome with risperidone. J Clin Psychopharmacol 16 (1996) 192-193
34. Margolese H.C., and Chouinard G. Olanzapine induced neuroleptic malignant syndrome with mental retardation. Am J Psychiatry 156 (1999) 1115-1116
35. Matsumoto R., Kitabayashi Y., Nakatomi Y., et al. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine. Am J Psychiatry 162 (2005) 812
36. Meterissian G.B. Risperidone-induced neuroleptic malignant syndrome: a case report and review. Can J Psychiatry 41 (1996) 52-54
37. Miller D.D., Sharafuddin M.J., and Kathol R.G. A case of clozapine-induced neuroleptic malignant syndrome. J Clin Psychiatry 52 (1991) 99-101
38. Muller T., Becker T., and Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 2 (1988) 1500
39. Najara J.E., and Enikeev I.D. Risperidone and neuroleptic malignant syndrome: a case report. J Clin Psychiatry 56 (1995) 534-535
40. Nyberg S., Farde L., and Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch Gen Psychiatry 54 (1997) 953-958
41. Otani K., Horiochi M., Kondo T., et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. Br J Psychiatry 158 (1991) 850-853
42. Pope H.G., Cole J.O., Choras P.T., et al. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174 (1986) 493-495
43. Reddig S., Minnema A.M., and Tandon R. Neuroleptic malignant syndrome and clozapine. Ann Clin Psychiatry 5 (1993) 25-27
44. Robb A.S., Chang W., Lee H.K., et al. Case study. Risperidone-induced neuroleptic malignant syndrome in an adolescent. J Child Adolesc Psychopharmacol 10 (2000) 327-330
45. Sachdev P., Kruk J., Kneebone M., et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 15 (1995) 365-371
46. Shalev A., Hermesh H., and Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 50 (1989) 18-25
47. Sharma R., Trappler B., Ng Y.K., et al. Risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 30 (1996) 775-778
48. Sierra-Biddle D., Herran A., and Diez-Aja S. Neuropletic malignant syndrome and olanzapine. J Clin Psychopharmacol 20 (2000) 704-705
49. Sing K.J., Ramaekers G.M., and van Harten P.N. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 159 (2002) 149-150
50. Solomons K. Quetiapine and neuroleptic malignant syndrome. Can J Psychiatry 47 (2002) 791
51. Stanfield S.C., and Privette T. Neuroleptic malignant syndrome with olanzapine therapy: a case report. J Emerg Med 19 (2000) 355-357
52. Suzuki A., Kondo T., Otani K., et al. Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 158 (2001) 1714-1716
53. Tarsy D. Risperidone and neuroleptic malignant syndrome. JAMA 275 (1996) 446
54. Tsai G., Crisostomo G., Rosenblatt M.L., et al. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 7 (1995) 91-95
55. Vetter P., Proppe D., and Hoppe-Seyler S. Neuroleptic malignant syndrome with clozapine monotherapy and benign hyperthermia after resolving neuroleptic malignant syndrome with clozapine. Two case reports. Nervenarzt 62 (1991) 55-57
56. Webster P., and Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 344 (1994) 1228-1229